Home
Service
Small Molecule Services
Macromolecular Services
In vitro ADME Screening Services
Animal Experimental Services
Daily Chemical Testing Service
Our Clients
COOPERATION CUSTOMERS
Apply immediately
Articles
Article published
Academic research
Guarantee
Quality Assurance
Organizational guarantee
Process assurance
Information Assurance
Technical support
News
Guochen Dynamic
Industry News
About Us
Company Profile
Enterprise culture
Development process
Contact Us
Leading the nuclear medicine track, opening the road of RLT commitment to China
On April 22, the 2024 Radiopharmaceutical Innovation and Development Conference hosted by the China Isotope and Radiation Industry Association was held in Beijing.
28
2024
/
04
Baili Tianheng's R&D investment in 2023 will increase by 99% year-on-year
On April 26, Baili Tianheng announced its 2023 performance, achieving operating income of RMB 562 million, a decrease of 20.11% from the same period last year. Net profit attributable to the listed company was RMB -780 million, a year-on-year decrease of 176.40%. The main reason was that during the reporting period, the Phase III clinical trial was carried out, and preclinical research and clinical trial research continued to be invested. With the continuous advancement of R&D progress, R&D investment increased, resulting in the company's R&D expenses continuing to grow.
27
Quantitative analysis of clinical biological samples of generic and innovative drugs
The pharmaceutical industry is related to national life, health and safety, and is highly valued worldwide. With the vigorous development of the global biomedical industry, the wave of innovation is one after another, and the scale of investment in pharmaceutical research and development is growing. CRO(Contract Research Organization, or contract research organization) industry market penetration is increasing, the industry development speed is obvious.
22
2023
09
Study on the whole set of drug preclinical application service and pharmacotoxicokinetics
Guided by the R & D needs of enterprises, gather large-scale instrument service resources across the country, closely link the platform service chain with the enterprise innovation chain, and effectively reduce the R & D costs of small and medium-sized enterprises. Through the four measures of "policy guidance, market configuration, model innovation, and service integration" At the same time, we will build a first-class science and technology public service platform based in Suzhou, serving the Yangtze River Delta, and radiating the whole country, which is open, networked and public.
In vivo ADME study
In 2022, China's in vivo ADME market capacity is 100 million yuan (RMB), and the global in vivo ADME market capacity is 100 million yuan. It is expected that the global in vivo ADME market capacity will grow at a compound annual growth rate of% during the forecast period and reach 100 million yuan in 2028.
探索临床生物样本检测的重要性
临床生物样本检测在医学诊断和治疗中起着至关重要的作用，通过分析血液、尿液、组织等样本，可以帮助医生准确判断病情，制定有效的治疗方案。
